Drug intelligence / Profile preview

FB 704A

Development stage: Phase 2
Lead developer: Oneness Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FB 704A is a fully human monoclonal antibody that targets and inhibits interleukin-6 (IL-6), a cytokine implicated in chronic inflammation. By blocking IL-6 activity, FB 704A aims to reduce inflammatory responses associated with diseases such as asthma and rheumatoid arthritis. The drug is being developed primarily for the treatment of severe asthma and has also been investigated in early-phase trials for rheumatoid arthritis and chronic kidney disease. The original developer was Fountain BioPharma, with current development led by Oneness Biotech. It is administered via intravenous infusion[1][2][5][6].

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on FB 704A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FB 704A.

Explore the full profile